Program - De-risking Secondary Pharmacology Mediated Adverse Effects as a Path to Develop Safer Medicines

De-risking Secondary Pharmacology Mediated Adverse Effects as a Path to Develop Safer Medicines

Tracks

Trianti Hall

Monday, June 24, 2024

1:45 PM - 3:45 PM

Trianti Hall

Overview

Organized by the British Pharmacological Society

Speaker

Dr. Jean-Pierre Valentin

UCB BioPharma

Challenges, opportunities and state of the art considerations for in vitro and in silico secondary pharmacology profiling

1:45 PM - 2:05 PM

Dr. Friedemann Schmidt

Sanofi-Aventis Deutschland GmbH

An IQ-DruSafe secondary pharmacology industry database analysis of current practices, experiences and recommendations for the future

2:05 PM - 2:25 PM

Dr. Sonia Roberts

Roche

Translational Pharmacology Case Studies: Intricacies of predicting patient risk from in vitro secondary pharmacology data

2:25 PM - 2:45 PM

Dr. Rebecca Racz

FDA

Analysis of Secondary Pharmacology Submissions to the US

2:45 PM - 3:05 PM

Dr. Jordi Mestres

Chemotargets

Translational Safety meets Pharmacovigilance

3:05 PM - 3:25 PM

Chair

Friedemann Schmidt

Sanofi-Aventis Deutschland GmbH

Jean-Pierre Valentin

UCB BioPharma

You need to enable JavaScript to access this site.

Follow these instructions on how to enable JavaScript.

Internet Explorer

Select Tools from the top menu
Choose Internet Options
Click on the Security tab
Click on Custom Level
Scroll down until you see the section labelled Scripting
Under Active Scripting, select Enable and click OK

Google Chrome

Select the menu icon on the browser toolbar
Select Settings
Click the Show advanced settings... link then Content Settings in the Privacy section
Select Allow all sites to run JavaScript (recommended) and click Done

Safari (Mac)

Select Safari from the top menu
Choose Preferences
Choose Security
Select the checkbox next to Enable JavaScript